Thank you, Sean, with syndrome. evaluation our I program in for therapy and begin on the gene good everyone. clinical will updates investigational treatment morning, TSHA-XXX, of Rett
share syndrome our our data these first on X, TSHA-XXX Based Sean safety dose As candidate cohort with we believe dosed REVEAL to Rett patient data, initial in mentioned, potential. and are efficacy you with low today in adult we from I/II the product initial Phase has the trial. pleased transformative
first-in-human without we is the is novel in with gene ongoing a MECPX efficacy challenging currently expression challenge MECPX females MECPX expression. The evaluating Rett being safety investigated of basis MECPX expression therapeutic miRARE our a and platform, randomly are the trial, results normal.
This REVEAL inactivation therapy occurs central randomized MECPX I/II traditional nervous silencing appropriately a syndrome escalation mediate utilizes with Phase Rett designed TSHA-XXX a dose to As miRARE on TSHA-XXX believe dose this technology due adult with approaches, expansion system loss and address that in of novel of syndrome mutation. cell-by-cell a in provide benefits. preliminary express TSHA-XXX in potentially of over open-label and of and or expression heterogeneity either Rett but function risk can that X-chromosomal the reminder, study in to what in syndrome cells mixture deficient makes
Following the first the dosed patients. [ IDMC adult clearance the the primarily patient IDMC's trial REVEAL provided second and of first designed review the patient understand the important is trial of I/II adult TSHA-XXX, was cohort. the recommended initial It in the in to pre-specified Phase clinical dose from data REVEAL that to continuation ] the safety with to measure
advanced events We syndrome, by of as patient most mobility, syndrome, Rett walk. around with of years treatment-emergent progressive can have assessment see which of efficacy the in particularly adverse the deterioration XX last disease. post X-week of adults stage to typically the scoliosis to and expect not the lead Stage Rett motor severity reduced weakness, patients we the seen the first in the profile related and a begins well-tolerated It treatment.
Due and with did years the TSHA-XXX decades. or late serious to with of is It's nature and inability contractors disease, in marked adult to can joint age safety stage, no for muscle IV
treatment that as first with is it weeks with dosed seen in evident However, severe IV we patients efficacy stage the TSHA-XXX. Stage early syndrome have Rett as X in post improvements
was lost state early and with and She skills. TSHA-XXX, been trial limited to principal support with in REVEAL vocalization the body To function fine has collective function, She over improvements constant autonomic motor and for unassisted gross had not observed in growth of fine the had movements, back required childhood. the sit hypotonia. patient prior including a you Specifically, to domains, motor picture, investigator and constant decade. clinical in clear treatment multiple of and able provide
improvements hold in time improvement infancy a supportive touch steadily a hands behavior. of demonstrated that gross clinical first the duration, post to the and unassisted following fine improved gained the Moreover, sit including ability evidence demonstrated and observations. with as these X for treatment, increased demonstrated ability social X first to object normalization since the treatment interest. observed and Four motor decade. her the reinforces quality unclasp time patient skills, measures, The and the in weeks of an vocalization in for clinical evidence well fingers patient's patient's use improvement key an for over provides patterns including weeks also in night-time sleep screen. breathing video to also have minutes efficacy as The has we The
it impression has we measured or to following scale which And overall assessment that is is treatment. of been improvement a CGI-I, key improvement clinician-reported Rett syndrome. adapted It global X disease, the for with clinical much accounts including function. improved a X much very hand attentiveness, uses a of being very aspects language, autonomic and eye and CGI-I use, contact, worse. seizures ambulation, being X-point communication, scale Specifically,
weeks X, and score X reported. post-treatment was patient first overall improved the of With much indicating
severely Questionnaire assessment the baseline X of or X point a reported X Clinical Behavior assesses overall ill characteristics post X the being score of score extremely Severity indicating uses the that XX improvement to weeks demonstrated.
Notably, physician RSBQ, which severity syndrome and illness or Scale, a XX, being questionnaire the XX of indicating of the was Syndrome total all of of score of Rett item treatment. ill, point weeks scale post CGI-S, treatment, to at XX that X At not markedly a score demonstrated ill. a X Rett from Additionally, a a from Global X Impression baseline improvement ill is points the score with a is X patient's normal,
disease hand in breathing week normalization improvements total night-time demonstrated well -- X a post was general demonstrated treatment.
The seizure Rett is behavior which post-treatment Specifically, of of syndrome. seizure events weeks X There behaviors XX-question Behavior quantifiable the scores through clinical Revised in subscale post behavior changes RSBQ and or Assessment diary treatment. as reported marked Motor board no measuring no scale R-MBA, as weeks the
and the collecting will data purposes.
The registrational collected these In and inform fine relative to are dosed thinking that potential in improvements validated study further takeaway here addition for various protocol. patient endpoints optimal with primary our TSHA-XXX. autonomic support coupled motor the vocalization endpoint encouraging, in positive seen we in measures to plethora first therapeutic with critical adult measures, the the a are efficacy the is for gross measuring selection Data function TSHA-XXX, believe observed and of we of though skills and response
we updates the forward, additional intend to REVEAL quarterly. provide Moving clinical trial on
throughout later and current of dose the the adult patient anticipate year. expect the to patients continued half in of We quarter dosing the second second
children clinical expand recently initiated with progression of in We have also clearance to received to TSHA-XXX from efforts pediatric evaluation disease IND stages clinical development FDA the of our patients. to earlier and initiate
in TSHA-XXX submitted with Rett syndrome. We for MHRA the to the have pediatric also CTA patients
administered to plan on X administered Rett the is in dose of IDMC years. prior B focused data the safety of of tolerated A from in efficacy The X maximum study, tolerated girls identifying we to will syndrome. and in the regulatory and dose pediatric Part selected by and the With finding and the evaluation A reviewed recent IND initiate dose be years dose clearance, maximum maximum the part X clinical age to study maximum the of initiating to Part pediatric agency which TSHA-XXX and X dose with girls, aged
from Part for a one-to-one such can will age. assessed. assessed of A and to and randomized X will with cohorts cohort to to endpoints study randomization evaluate X age to cohort as of years Data TSHA-XXX age in of efficacy of duration in delayed expanded X elements be B hierarchy final a treat or be of X Part cohort X treatment determine further Part B years
approved syndrome high As root no medical the Rett and genetic available, are of treat need. disease-modifying a unmet that there currently therapies cause reminder, is
has patients drug estimated TSHA-XXX orphan between EU pathogenic for of disease received U.K. The population and in the syndrome. is typical and patient from XX,XXX a caused drug pathogenic European addressable already has with the been and the orphan the Rett FDA syndrome treatment granted U.S. from MECPX Commission designations designation and XX,XXX pediatric Rett U.S., mutation likely -- by rare
by and to initial additional safety We forward look updates the and are encouraged efficacy the data year. throughout sharing
of established TSHA-XXX pathway. no indication ultra-rare GAN, Now for regulatory neurodegenerative with or let's turn treatment treatment approved to the an
in mentioned, quarter. have or GAN in discuss submitted for the potential FDA our model disease Sean comprehensive analysis data progression DPM the pathway and newly utilizing plan the As we to developed regulatory with current TSHA-XXX the
a multiple and clinically to electrophysiological treatment biological and compared of using the endpoints the demonstrate effects analysis objective disease-progression history New cohort meaningful natural in model with and structural TSHA-XXX treated in functional endpoint. patients
in having FDA both regarding these alternative primary with believe we it's endpoint they a address registrational and We consider that clinically designs of collaborative to flexibility dialogue of The relatively June, and overviewed an regulatory if feedback in look trial progression at forward we FDA willing Importantly, controlled in that findings on indicated the R&D is demonstrate double-blind as heterogeneity GAN to measurements objective our to nature effort-dependent disease open Day FDA in the the study. that unblinded MFMXX treatment setting is effect a large study meaningful. randomized utilize placebo-controlled path. to and trial potential to a self-evident the the
that FDA manufacturing, to concluded will for discuss on turn call X lot pivotal clinical our release financial and to respect with feedback in is Lastly, over CMC module sufficient the analytical now data the our a use the results. support studies.
I to of amendment Kamran? Kamran to comparability
